Share this article
Share this article
ResearchAndMarkets.com s offering.
The global protein A resin market is projected to reach USD 1,916.3 million by 2025 from an estimated USD 1,115.8 million in 2020, at a CAGR of 11.4% during the forecast period.
The protein A resin market has witnessed increasing consumption due to increased monoclonal antibody production on account of the pandemic situation worldwide.
Growth in the market can primarily be attributed to factors such as demand for pre-packed disposable columns, increasing demand for therapeutic antibodies, and increasing pharmaceutical R&D spending
The agarose-based protein A segment to hold the largest market share in 2020.
Based on product, the protein A resin market is segmented into agarose-based protein A, glass/silica-based protein A, and organic polymer-based protein A. In 2020, the agarose-based protein A segment is expected to command the largest share of the protein A resin market. The large share of this segmen
Press release content from Wired Release. The AP news staff was not involved in its creation.
Global Viral Clearance Market Size Worth $ 712.7 Mn with CAGR of 11.7% by 2030 | Top Industry Trends and Outlook
January 28, 2021 GMT
Pune, Maharashtra, January 28 2021 (Wiredrelease) Market.Biz :Global Viral Clearance Market Overview and Analysis by Application (Recombinant Proteins, Blood and Blood Products, Vaccines, Other Applications), Types (Viral Removal, Chromatography, Nanofiltration, Precipitation, Viral Inactivation, Low pH, Solvent Detergent Method, Pasteurization, Other Viral Inactivation Methods), Company (Wuxi Biologics (Cayman), Merck, Charles River Laboratories International, Kedrion, and more), Size, Share, Region, Forecast to 2030.
The economic world for Viral Clearance market has never evolved as quickly and as deeply as today. Despite the obvious disruptions caused by COVID-19, the future for Viral Clearance Industry looks bright in coming years. Global Viral Clearan
Bio-pharma Market to see Huge Growth by 2025 | Pfizer, Amgen, Biogen Idec texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
ProBioGen Licenses GlymaxX® Technology to AbbVie
Search jobs
ADCC-Enhancement for Innovative Therapies
BERLIN, Germany, January 21, 2021 / B3C newswire / ProBioGen AG has signed a commercial license agreement with AbbVie for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody-dependent cell-mediated cytotoxicity (ADCC).
The proven GlymaxX
® technology for production of afucosylated proteins is universally applicable, simple and potent. The unique advantage of the GlymaxX
® technology is that a single GlymaxX
® modified cell line is sufficient to produce both, completely fucosylated or afucosylated antibodies and those with an intermediate defined fuscosylation level. The technology can easily be integrated in newly developed or already existing cell lines of different origins.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The global cell culture market is projected to reach USD 33.1 billion by 2025 from USD 19 billion in 2020, at a CAGR of 11.8% during the forecast period.
The growth of this market is majorly driven by the growing awareness about the benefits of cell culture-based vaccines, increasing demand for monoclonal antibodies (mAbs), funding for cell-based research, growing preference for single-use technologies, and the launch of advanced cell culture products. On the other hand, the high cost of cell biology research and the lack of proper infrastructure for cell-based research activities are the major factors restraining this market s growth.